- Details
- Andrea Apolo, Pavlos Msaouel, and Petros Grivas discuss findings and recommendations shared during an ASCO presentation on clinical trial endpoints in the adjuvant setting for RCC kidney cancer and urothelial cancer. The conversation touches on trial design and efficacy, as well as concerns about treatment burden, toxicity, cost, and survival benefit. Patient advocacy and patient-specific issues r...
|
- Details
- Alicia Morgans is joined by Toni Choueiri in a discussion on integrating therapies earlier in the treatment landscape for renal cell carcinoma (RCC), specifically highlighting the HIF-2α inhibitor and the phase 2 study of belzutifan plus cabozantinib as first-line treatment of advanced RCC, the LITESPARK-003 study. This was an oral presentation at the 2022 ESMO meeting. Belzutifan, a first-in-clas...
|
- Details
- Alicia Morgans is joined by Toni Choueiri in a discussion on the COSMIC-313 examining the role of triplet therapy with cabozantinib, nivolumab and ipilimumab as first-line treatment in patients with advanced renal cell carcinoma (RCC). The COSMIC-313 trial made strides at the 2022 ESMO meeting being a presidential symposium reporting the first phase 3 clinical trial in advanced RCC to use a contem...
|
- Details
- Ricardo Fernandes joins Pedro Barata in a discussion on PERFORM, an ongoing phase I study evaluating the safety of fecal microbiota transplantation (FMT) and immunotherapy combination in first-line (1L) metastatic renal cell carcinoma, and assessing whether FMT will prevent or mitigate immune-related adverse events. Dr. Fernandes details what led to the design and conduct of PERFORM. The study aim...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the OMNIVORE study published in the Journal of Clinical Oncology. This phase II response-adaptive trial investigated the rational application of immune checkpoint blockade in renal cell carcinoma. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto. Zachary Klaassen, MD, MSc, Ur...
|
- Details
- Marc-Oliver Grimm joins Pedro Barata in a discussion on the final results of the TITAN-RCC trial, assessing a tailored approach to systemic therapy in patients with metastatic renal cell carcinoma (mRCC). The TITAN-RCC was designed many years ago, when nivolumab + ipilimumab (NIVO/IPI) was not approved yet as a first-line treatment. During this time the pivotal CheckMate 214 trial was still in pro...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss an update on the CARMENA trial. CARMENA was a phase III trial in 450 patients with metastatic renal cell carcinoma (mRCC) enrolled from 2009 to 2017. The objective of this study was to provide updated overall survival (OS) outcomes of CARMENA and assess whether some subgroups may still benefit from upfront cytoreductive nephrectomy. Biographies: Chri...
|
- Details
- Axel Bex joins Alicia Morgans to discuss the results of the NeoAvAx trial examining neoadjuvant avelumab and axitinib following nephrectomy for patients who are at high risk for recurrence. The NeoAvAx trial tests the neoadjuvant use of a combination of the immune checkpoint inhibitor avelumab and the VEGF-inhibitor axitinib. Biographies: Axel Bex, MD, PhD, Urologic Surgeon, Royal Free London NHS...
|
- Details
- Medical Oncologist and member of the scientific committee of the upcoming European International Kidney Cancer Symposium, Samra Turajlic joins Rana McKay to discuss the upcoming IKCS meeting being held April 22nd through the 24th in Antwerpen, Belgium. The program will consist of Award Lectures in Urology and Oncology, Basic Science in renal cell carcinoma (RCC), Biomarkers in RCC, Diagnostics, an...
|
- Details
- Alicia Morgans is joined by Toni Choueiri to discuss his GU ASCO 2022 presentation on a 30-month follow-up from the KEYNOTE-564 trial of post-nephrectomy adjuvant pembrolizumab in patients with renal cell carcinoma (RCC). Dr. Choueiri highlights that adjuvant pembrolizumab continued to demonstrate a disease-free survival (DFS) benefit following nephrectomy for patients with intermediate-high or hi...
|
